Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vancomycin or Semi-Synthetic Penicillins (SSPs)
Vancomycin or Semi-Synthetic Penicillins · 1 trial · 1 indication
Success: Clinically significant signs and symptoms associated with the skin infection present at the pre-treatment infection site resolved (cure), or improved without need of further antibacterial therapy. Failure: Persistence or progression of signs and symptoms or development of new clinical signs and symptoms at the infection site, or concomitant antibacterial therapy with activity against isolated organisms, or treatment duration longer than pre-specified, or switch back to intravenous therapy due to relapse, or requirement of a major surgical procedure as adjunct or follow-up therapy.
| Arm | Type | Description |
|---|---|---|
| Daptomycin | EXPERIMENTAL | Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days. Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days. |
| Vancomycin or Semi-Synthetic Penicillins (SSPs) | ACTIVE_COMPARATOR | Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days. Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days. |
| Name | Type | Description |
|---|---|---|
| Daptomycin | DRUG | Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days. Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days. |
| Vancomycin or Semi-Synthetic Penicillins (SSPs) | DRUG | Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days. Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days. |
Inclusion criteria: Patients 65 years or older with infection of sufficient severity to require in-patient hospitalization, with parenteral antimicrobial therapy for at least 96 hours. Patients who have a diagnosis of Gram-positive complicated Skin and Soft Tissue Infections (cSSTIs) with or witho...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Vancomycin or semi-synthetic penicillins are antibiotic treatments used for infections. They are studied in infectious disease, including complicated skin and soft tissue infections. In the Phase 3 trial NCT01184872, they served as the active comparator against which daptomycin was evaluated in elderly patients aged 65 years and older.
Novartis AG, which trades under the ticker NVS, is the developer associated with vancomycin or semi-synthetic penicillins. The company sponsored the Phase 3 study NCT01184872, which compared daptomycin with these antibiotics in elderly patients with complicated skin and soft tissue infections.
Vancomycin or semi-synthetic penicillins have been studied in a Phase 3 clinical trial. That study, NCT01184872, is completed and enrolled 120 participants. The trial was randomized and active controlled, meaning patients received either the study drug or vancomycin or semi-synthetic penicillins as the comparator.
Vancomycin or semi-synthetic penicillins were evaluated in the Phase 3 trial NCT01184872, titled Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections. The trial enrolled 120 patients aged 65 years and older across Austria, Germany, Italy, Russia, and Spain, and it is now completed.
Yes, semi-synthetic penicillins are commonly abbreviated as SSPs, so vancomycin or semi-synthetic penicillins (SSPs) refers to the same antibiotic comparators. The abbreviation appears alongside the full name in reference to the active control arm used in the Phase 3 trial NCT01184872.
Vancomycin or semi-synthetic penicillins were studied in infections, specifically complicated skin and soft tissue infections. In the completed Phase 3 trial NCT01184872, they were the active control compared with daptomycin in patients aged 65 years and older, with enrollment of 120 participants across five European countries.